Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial

The potent in-vitro effects of hydroxychloroquine (HCQ) against SARS-CoV-2 has not convincingly been translated into clinical benefits in patients with COVID-19. A non-randomized trial showed significantly higher virus clearance rate at 6-day post inclusion in patients receiving 600mg hydroxychloroquine daily (N=20) than in patients with standard-of-care (N=16)

Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial
Size: 2 MB